Failure of Natalizumab to Prevent Relapses in Neuromyelitis Optica

Ingo Kleiter
2012 Archives of Neurology  
Objective: To describe first experiences with the integrin inhibitor natalizumab, given to patients with suspected relapsing-remitting multiple sclerosis (MS) who were later diagnosed with aquaporin 4-positive neuromyelitis optica (NMO). Design: Retrospective case series. Setting: Neurology departments at tertiary referral centers in Germany. Patients: Patients with NMO who tested positive for antibodies to aquaporin 4. Intervention: Treatment with natalizumab. Main Outcome Measures: Relapses
more » ... easures: Relapses and accumulation of disability. Results: We identified 5 patients (4 female; median age, 45 years) who were initially diagnosed with MS and treated
doi:10.1001/archneurol.2011.216 pmid:22332191 fatcat:sqoj4yvtijavdctrcv53ncdq4m